Liposomal Annamycin Shows Synergistic Anti-Cancer Activity with Existing Chemotherapies in Preclinical Hematologic and Solid Tumor Models

Liposomal annamycin exhibits synergistic effects with several FDA-approved chemotherapies in preclinical models. These findings span both hematologic and solid tumors, suggesting a broad potential application. Researchers observed the synergistic activity in laboratory settings. Specifically, the study showed that when liposomal annamycin was combined with existing chemotherapeutic drugs, the combination displayed enhanced anti-cancer activity. The observed synergy occurred across a range of hematologic cancers, which originate in the blood or bone marrow, and solid tumors, which are abnormal masses of tissue. The researchers note that the preclinical models suggest the potential for a combination strategy in treating resistant and high-risk cancers.

Newsflash | Powered by GeneOnline AI
Date: May 1, 2025

Author

Mark Chiang